ACP6 Activators
ACP6 activators are compounds that influence the cellular lipid milieu, either by modifying the levels of bioactive lipids or by affecting the signaling pathways that control the metabolism of these lipids. These chemicals can indirectly activate ACP6 by increasing the availability of its substrate or by altering the balance of signaling molecules that control its activity within the cell.
Compounds like sphingosine-1-phosphate and FTY720 (Fingolimod) engage with sphingosine-1-phosphate receptors, which can lead to a cascade of effects on lipid signaling pathways that indirectly influence ACP6. Agonists such as SEW2871 and antagonists like VPC 23019 and CAY10444 target the receptors of bioactive lipids and may alter the concentration of lysophosphatidic acid in the cellular environment, thereby modulating the activity of ACP6. GW9662 and LY294002 impact broader lipid and protein kinase signaling mechanisms, thus they have the potential to indirectly influence ACP6 activity by changing the intracellular context in which ACP6 operates. Inhibitors like PF-543 and CID755673 target enzymes upstream of ACP6, such as sphingosine kinase and protein kinase D respectively, affecting the balance of lipid signaling molecules and potentially leading to changes in ACP6 activity. Compounds like D609 and Manumycin A interfere with other aspects of lipid metabolism and signal transduction, which could indirectly modulate the activity of ACP6
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
A bioactive lipid that, by signaling through its receptors, can modulate intracellular levels of LPA, thereby indirectly influencing ACP6 activity. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
A sphingosine-1-phosphate receptor modulator that can impact LPA signaling cascades, potentially affecting the balance of substrates available for ACP6. | ||||||
SEW2871 | 256414-75-2 | sc-203251 sc-203251A | 5 mg 10 mg | $38.00 $53.00 | 1 | |
A selective agonist for sphingosine-1-phosphate receptor 1 (S1P1), which may alter LPA levels and thereby the activity of ACP6. | ||||||
VPC 23019 | 449173-19-7 | sc-362817 | 10 mg | $364.00 | 4 | |
A dual S1P receptor antagonist that could shift the equilibrium of lipid signaling molecules, possibly affecting ACP6’s substrate availability. | ||||||
2-undecyl-thiazolidine-4-carboxylic acid | 298186-80-8 | sc-220768 sc-220768A | 5 mg 10 mg | $88.00 $166.00 | ||
An LPA receptor antagonist that might change the intracellular concentration of LPA, thus influencing ACP6 activity. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
A PPARγ antagonist that might indirectly affect lipid metabolism and signaling pathways involving ACP6. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could modify the lipid signaling milieu and indirectly affect the pathways in which ACP6 is active. | ||||||
PF-543 | 1415562-82-1 | sc-507507 | 10 mg | $210.00 | ||
A sphingosine kinase inhibitor that potentially reduces sphingosine-1-phosphate levels, thus modulating the activity of ACP6 indirectly. | ||||||
ATM/ATR Kinase Inhibitor Inhibitor | 905973-89-9 | sc-202964 | 5 mg | $106.00 | 8 | |
A PKD inhibitor that may influence lipid signaling pathways and alter the function of ACP6. | ||||||
D609 | 83373-60-8 | sc-201403 sc-201403A | 5 mg 25 mg | $189.00 $575.00 | 7 | |
An inhibitor of phosphatidylcholine-specific phospholipase C that could impact LPA metabolism and indirectly affect ACP6 activity. | ||||||